»¶Ó­À´µ½Öйú»¯Ñ§»á¹Ù·½ÍøÕ¾£¡

·ÃÎÊаæÍøÕ¾ | ¹ØÓÚÎÒÃÇ

ËùÔÚλÖãºÖйú»¯Ñ§»á > »áÒéרÌâ > Öйú»¯Ñ§»áµÚ30½ìѧÊõÄê»á

Äê»á±¨¸æÈÕ³Ì±í¡¡ ÏÂÔØ£ºÖйú»¯Ñ§»áµÚ30½ìѧÊõÄê»áÈÕ³ÌÊÖ²á.pdf

»áÒéÃû³Æ£ºÖйú»¯Ñ§»áµÚ30½ìѧÊõÄê»á
·Ö»áÃû³Æ£ºµÚ¶þÊ®°Ë·Ö»á£º»¯Ñ§ÉúÎïѧ
¡¡×¢£ºPL-´ó»áÌØÑû±¨¸æ(Plenary Lecture) I-·Ö»áÑûÇ뱨¸æ(Invited) O-¿ÚÍ·±¨¸æ(Oral) P-ǽ±¨(Poster) A-×ÔÓɽ»Á÷
2016-07-02
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÖÜÏè£¬Ï¯Õæ
09:05-09:3028-I-001ÕÅÀñºÍ»ùÓÚ»¯Ñ§ÉúÎïѧµÄ´´ÐÂÒ©ÎïÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
09:30-09:5528-I-002µËºê¿ýSmall Molecule-induced Cell Fate ReprogrammingÌí¼Óµ½ÎÒµÄÈÕ³Ì
09:55-10:2028-I-003Ëα¦°²Öش󲡶¾²¡µ¼ÏòµÄÂÌɫũҩ»¯Ñ§Ñо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºËα¦°²£¬À´Â³»ª
10:35-11:0028-I-004À´Â³»ªµ°°×Öʱ𹹵÷¿Ø·Ö×ÓÉè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
11:00-11:2528-I-005³ÂÐË´óÄÔÌÇ»ù»¯µÄ±ê¼ÇÓë³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
11:25-11:4028-O-001Ф½¨Ï²½ºÔ­µ°°×ÈýÖØÂÝÐý½á¹¹µÄ¼ì²â·½·¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
11:40-11:5528-O-002Öܽ­CCND1Æô¶¯×ÓÇø´®ÁªËÄÁ´ÌåµÄÐγɡ¢Ê¶±ðÓëת¼ÒÖÖÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
11:55-12:1028-O-003¬ÖÒÁÖº¬Ó«¹âµ¥Ôª[12]aneN3»¯ºÏÎïºÏ³É¼°ÆäDNAÄý¾Û¡¢·Ç²¡¶¾»ùÒòÔØÌåÌí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÇúÏþ¸Õ£¬ÑÕÏþ÷
13:30-13:5528-I-006ÑÕÏþ÷µ¥ÏßÁ£Ìåˮƽ¶à²ÎÊý¸ßͨÁ¿¼ì²âµÄÐźÅתµ¼Ñо¿Ó¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
13:55-14:2028-I-007ÇúÏþ¸ÕºËËáµÄ·Ö×Óʶ±ð»úÖÆ¼°ÆäÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:20-14:3528-O-004ÖÜ´«Õþ5-Methylene Maleimides for Cysteine BioconjugationÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:35-14:5028-O-005ºØÏþÅôÌÇ·Ö×Ó̽ÕëµÄ¹¹½¨ÓëÈËÀàÖØ´ó¼²²¡Õï¶ÏÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:50-15:1528-I-026Ñî¹â¸»°Ð±êµ¼ÏòµÄÌìÈ»²úÎï½á¹¹ÓÅ»¯Ìí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÁõÎÄ£¬ÕÔ×Ú±£
15:20-15:4528-I-008ÁõÎÄÁÖ¿ÉÃ¹ËØµÄÉúÎïºÏ³É£ºÁ½¸öС·Ö×ÓÁò´¼µÄ¹ÊÊÂÌí¼Óµ½ÎÒµÄÈÕ³Ì
15:45-16:1028-I-009ÑîÕñ¾üÒìºËÜÕÁªºÏ2¡¯-ÍÑÑõ¼¡ÜÕÐÞÊκËËáÊÊÅäÌåAS1411,ÆäÉúÎï»îÐԺͷÖ×Óµ÷¿Ø»úÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
16:10-16:3528-I-010Áõ¸ÕConmutaxol inhibits tumor metastasis through blocking NOD1/2 mediated NF-B and MAPKs signalingÌí¼Óµ½ÎÒµÄÈÕ³Ì
16:35-17:0028-I-011ÕÔ×Ú±£Ð¡·Ö×Óµ÷¿Ø½Íĸ֬ÖÊ´úлÌí¼Óµ½ÎÒµÄÈÕ³Ì
17:00-17:1528-O-007ÀîÀ¤ÏßÁ£Ìå°ÐÏòµÄSO2Ó«¹â̽Õë¼°»îϸ°û³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
17:15-17:3028-O-008²Ü´ºÑô²ÎÓ뿹Ö×ÁöÒ©ÎïFR901464ÉúÎïºÏ³ÉµÄø´ß»¯»úÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
17:30-17:4528-O-009ÕźÀ´´ÐÂÒ©Îï·¢ÏÖ¼°µ°°×Öʶ¯Ì¬µ÷¿ØÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
17:45-18:0028-O-010Íõ½¨¹ú°ÐÏòÒÒõ£ÈéËáºÏ³ÉøµÄ¿¹Ö²¡Õæ¾úÒÖÖÆ¼ÁÌí¼Óµ½ÎÒµÄÈÕ³Ì
2016-07-03
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÀîÑÞ÷£¬»ÆÖ¾ç£
08:30-08:5528-I-012ÀîÑÞ÷»ùÓÚ»¯Ñ§ºÏ³ÉÒßÃçµÄÖ×ÁöÃâÒßÁÆ·¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
08:55-09:2028-I-013»ÆÖ¾ç£¿¹·ÊÅÖÖ¢Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¼°·Ö×Ó×÷ÓûúÖÆÑо¿Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¼°·Ö×Ó×÷ÓûúÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
09:20-09:3528-O-011Ì·¼ÎºãÌØÒìÐÔG-ËÄÁ´ÌåÓ«¹â̽ÕëµÄ¿ª·¢ÓëÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
09:35-09:5028-O-012ÌÀо°Reduce off-target effect of RNA interference with circular siRNAsÌí¼Óµ½ÎÒµÄÈÕ³Ì
09:50-10:0528-O-013Íõ»¶¶àëÄÌìÈ»²úÎïµÄÉúÎïºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÓàТÆä£¬ÑÓÂ
10:20-10:4528-I-014Ï¯ÕæÖ§Á´PCR¸ßÐ§ÖÆ±¸»ùÒòÄÉÃ×ÔØÌåÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:45-11:1028-I-015ÑÓµ¥Ï¸°û·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
11:10-11:3528-I-016ÓàТÆä¸ßЧ¸ßÉúÎïÏàÈÝÐÔ¾ÛºÏÎï»ùÒòÔØÌåµÄ¹¹Ð§¹ØÏµÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
11:35-11:5028-I-017ÍõÏþ»Ô¶¾Æ·µÄÉñ¾­ÌìÈ»ÃâÒß×÷Óü°Ò©Îï·¢ÏÖÌí¼Óµ½ÎÒµÄÈÕ³Ì
11:50-12:0528-O-014×ÞÅô»ùÓÚAPEX¼¼ÊõµÄ¿Õ¼äÌØÒìÐÔµ°°×ÖÊ×é±ê¼ÇÌí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£º½ªÖ¾ºê£¬Àî³Զ
13:30-13:5528-I-018½ªÖ¾ºêÈ˲ÎRNAµÄ¿¹Ðļ¡È±Ñª»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
13:55-14:2028-I-019Àî³ԶA molecular switch that controls oxygen-independent degradation of hypoxia-inducible factor-1¦ÁÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:20-14:3528-O-015Ìï›pG-ËÄÁ´ÌåRNA×÷ΪÐÂÐÍ¿¹±û¸Î²¡¶¾°Ð±êµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
14:35-14:5028-O-016ÁõÏþºì»ùÒò±àÂë·ÇÌìÈ»°±»ùËáÀ©Õ¹Ó«¹âµ°°×ÐÔÖÊÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:50-15:0528-O-017λµÆ¹úC-kit1Æô¶¯×ÓÇøÓòG-ËÄÁ´Ìå¾§Ìå½á¹¹½Òʾ½ðÊôÀë×ÓÌí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ººÂС½­£¬Ò¶ÐÂɽ
15:20-15:4528-I-020ºÂС½­µ°°×¼¤Ã¸CÒÀÀµµÄÈÜøÌå·¢ÉúлúÖÆµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
15:45-16:1028-I-021Ì·Äþ»ª°ÐÏòÑ×°©¼°Æä×ªÒÆµÄÐÂÐÍÌìÈ»»·ëÄRAsµÄ»¯Ñ§ÉúÎïѧÓë´´ÐÂÒ©Ñо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
16:10-16:3528-I-022Ò¶ÐÂɽ¿¹Ö×ÁöÌÇÒßÃçÑо¿½øÕ¹Ìí¼Óµ½ÎÒµÄÈÕ³Ì
16:35-17:0028-I-023Ñî²Æ¹ã»¯Ñ§Ì½Õ롪»¯Ñ§ÉúÎïѧ´Ù½øÐÂÒ©·¢ÏÖÖ®ÇÅÌí¼Óµ½ÎÒµÄÈÕ³Ì
17:00-17:1528-O-018ÁõÌï»ùÓÚÀ¥³æN-ÒÒõ£¼ºÌǰ·Ã¸½á¹¹µÄÒÖÖÆ¼ÁÉè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
17:15-17:3028-O-019Wen ZhangThe Design, Synthesis of Chirally-modified Polyamides and Their Bioactivity of Anti-tumors by Downregulating PD-1 GeneÌí¼Óµ½ÎÒµÄÈÕ³Ì
17:30-17:4528-O-020¸ßÔ¶»îÌåÄÚ³¬·Ö×Ó×Ô×é×°ÓÃÓÚÖ×ÁöÕï¶ÏÖÎÁƵÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
17:45-18:0028-O-021ÁõÎä¾üº¬ÀàÒìÎì¶þϩ̽Õë·Ö×Ӻϳɼ°ÆäÓëøµÄÏ໥×÷ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
2016-07-04
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£º¾ÏŸºÏÈ£¬ÑîÕñ¾ü
08:30-08:5528-I-024¾ÏŸºÏÈϸ°û¹¦ÄÜ·Ö×ÓµÄԭλ³ÉÏñ¼ì²â¼°ÆäÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
08:55-09:2028-I-025·½Ïþºìµ¥·Ö×ÓÓ«¹â³ÉÏñÑо¿Ò©Îï¶ÔÉöÉÏÏÙËØÊÜÌåµÄÑ¡ÔñÐÔ¼¤»îÌí¼Óµ½ÎÒµÄÈÕ³Ì
09:20-09:3528-O-022Íõ³õÌìÈ»ÖвÝÒ©µÄ»¯Ñ§µ°°×ÖÊ×éѧ¼°½µÖ¬ÁÆÐ§µÄ»úÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
09:35-09:5028-O-023ÎâÀöÄȵ¥Ï¸¾úˮƽµ°°×ÖÊÏ໥×÷ÓõĸßͨÁ¿¶¨Á¿¼ì²âз½·¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
09:50-10:0528-O-024Ö£Îĸ»»ùÓÚ΢Á÷¿ØÐ¾Æ¬µÄ¶¯ÂöÖàÑùÓ²»¯Ñо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥×Û253 Ö÷³ÖÈË£ºÏ¯Õ棬ÖÜÏè
14:00-14:1528-O-025ÒÁ³ÉÆ÷ºËËá±í¹ÛÒÅ´«ÐÞÊεĻ¯Ñ§²âÐòÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:15-14:3028-O-026·®ÐÂÔª·´Ê½»·ÐÁÏ©´¥·¢µÄ¶Ï¼ü·´Ó¦ÔÚµ°°×Öʹ¦Äܼ¤»îÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
14:30-14:4528-O-027ÏÄÇàÒÖÖÆÐÔtRNA¶Ô¶ÅÊϼ¡ÓªÑø²»Á¼¼²²¡µÄÖÎÁÆÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
14:45-15:0028-O-006Ô¬±Ø·æ»¯Ñ§±ê¼Ç-ÒºÏàÉ«Æ×ÖÊÆ×·ÖÎöÓÃÓÚºËËá±í¹ÛÒÅ´«ÐÞÊÎÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
15:10-15:3528-I-027ϯ½¨ÖÒmiR-122 ½éµ¼¸ÎÖ×Áö΢»·¾³·¢²¡»úÖÆ¼°¿¹Ö×ÁöÌìÈ»»îÐԳɷÖɸѡÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
15:35-16:0028-I-028½¯»ªÁ¼¼ÆË㣺µ°°×Öʽṹ-¹¦ÄÜ-µ÷¿ØÑо¿µÄÖúÍÆÆ÷Ìí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥ Ö÷³ÖÈË£ºÒ¶ÐÂɽ£¬ÀîÑÞ÷£¬ÓàТÆä£¬ÑÓÂ
10:05-12:0528-P-001Li-Ping BaiCardenolides as Inhibitors of Hypoxia-Inducible Factor-1 Transcriptional ActivityÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-002ÕÅÑå·åʵʱ׷×ÙС·Ö×Ӻ͸߷Ö×ÓÒ©Îï׺ºÏÎïµÄÒ©ÎïÊͷŹý³ÌÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-003´ÞÊ«»Û¼×Ëáõ¥ÐÍëÄÖ¬ÖÊÌåµÄ°±»ùËáÊýÁ¿¶Ô»ùÒòתÔËÐÔÄܵÄÓ°ÏìÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-004ÀîçùºËËáËðÉËAlkBÐÞ¸´Ã¸°Ð±êÑéÖ¤Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-005ÖÜ¿­ÏèÒÔD-¦Ð-AΪ»ù±¾¹Ç¼ÜµÄÓÃÓÚÄÔÄÚµí·ÛÑù°ß¿é¼ì²âµÄ½üºìÍâ̽ÕëµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-006Ðí¾²âùÏßÁ£ÌåµòÍöͨ·Ĥµçλ½µµÍÓëϸ°ûÉ«ËØCÊͷŵÄÏ໥¹ØÏµÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-007Àî骵¥·Ö×ÓÓ«¹â³ÉÏñÑо¿TGF-beta ÐźÅͨ·ÏÂÓε°°×Smad7µÄÒÖÖÆ»úÀíÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-008¹ùµÀϼ»ùÓÚÓ«¹â¹èÄÉÃ׿ÅÁ£Ò©ÎïÔØÌåµÄÄÍÒ©ÐÔÖÎÁÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-009ÕÅÏþ·ÒpHÃô¸ÐµÄ¾Û¼×»ù±ûÏ©Ëá¿ÕÐÄÄÉÃ×ÇòÓÃÓÚÒ©ÎïÊͷźͳ¬Éù³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-010»ÆÀÚ»ùÓÚ¹âµã»÷·´Ó¦µÄMicroRNA̽ÕëµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-011ºÎ²¨à­ßòßø¶þͪÑÜÉúÎïµÄºÏ³É¼°ÉúÎï»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-012Íõµ¤»ùÓÚ˫ӫ¹âËØÃ¸±¨¸æÌåϵµÄCas9»ùÒòÇиî»îÐÔ¶¨Á¿¼ì²âÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-013ÁõÃÈ4-ôÇ»ù±½¼×È©-2-°±»ùàçßò-4-¼×õ£ëêµÄºÏ³ÉºÍ±íÕ÷Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-014Áõ±ù»ùÓÚDNAÕÛÖ½ÊõµÄÄÉÃ×½ð°ô¾«ÃÜÐÞÊÎÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-015²ÌСÀöZnOÔØÒ©ÌåϵµÄ¹¹½¨¼°ÆäÔڷΰ©Ï¸°ûÕïÁÆÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-016ÁõÓ¨PLK1¼¤Ã¸KDµÄ±ð¹¹ÒÖÖÆ¼ÁÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-017Ô·Ç¿ÌξßÓжàģʽ̽Õ빦ÄܵÄË«ºËпÅäºÏÎïÉè¼ÆºÏ³É¼°Æä¶ÔǰÁÐÏÙ°©µÄ³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-018ÀîÁÉÁÉÜÅÀàÑÜÉúÎï×÷ΪһÀàÐÂÐ͹âÉù³ÉÏñ²ÄÁϵÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-019ÕÅ¿­ÁúÒ»ÖÖ»ùÓÚ³¤Ñ­»·Ñõ»¯ÌúÄÉÃ×½ºÊøµÄ¸ßÐÔÄÜT2´Å¹²ÕñÔìÓ°¼ÁÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-020ÕÔÒ»À×DNAÁòÐÞÊεĽṹÓ빦ÄÜÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-021ºúÎıóͨ¹ýµã»÷»¯Ñ§·´Ó¦ÖƱ¸Î»µãÌØÒìµÄÓ«¹â¸ß·Ö×Ó-µ°°×ÖʽáºÏÌåÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-022ФäìmicroRNAÄÉÃ׸´ºÏÎïÓÃÓÚmicroRNA°ÐÏòÔËÊäÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-023ÌïÌðÑôÀë×ÓÖ¬ÖÊÌåÓë»ùÒò¸´ºÏÎïµÄ½áºÏ¶¯Á¦Ñ§Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-024ºúÌÎDPIʵʱ̽Ë÷A¦Â1-42ºÍLilrb2 receptorÏ໥×÷Óõ͝Á¦Ñ§»úÖÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-025Hua ChenSynthesis of tetracyclic iminosugar derivatives fused thiazinan-4-one as potential HIV-RT inhibitorsÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-026ÇúÈÊÓåÐÂÐÍà×à¤Àà·´¿¹ÐÔAHASÒÖÖÆ¼ÁµÄÉè¼Æ¡¢ºÏ³ÉÓëÉúÎï»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-027Íõ¼Ñç÷»ùÓÚBst ¾ÛºÏø¶¨Á¿ÆÀ¹ÀDNAºÍRNAÖеÄm6AÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-028Áõ½¨¾üÖÇÄÜÏìÓ¦ÐÍ΢½ºÄÒÔÚϸ°ûÄڵĿØÖÆÊÍ·ÅÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-029¼ÍîÚË®ÈÜÐÔ¹²éî¾ÛºÏÎï×÷Ϊģ°æºÏ³É½ðÄÉÃ׿ÅÁ£ÔÚ¹âÉù³ÉÏñÖ¸µ¼ÏµÄÕïÁÆÒ»Ì廯Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-030ÍõѩӱÉúÎïºÏ³É¸¨Ã¸ÀàËÆÎïÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-031ÁõÓñѩɸ²éÑõ»¯»¹Ô­Ã¸¸¨Òò×ÓÆ«ºÃÐÔÏà¹ØµÄÍ»±äÈȵãÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-032ÐìËÄ´¨×ó±½±û°·ÔÚ¶à°Í°·µÚÈýÊÜÌåͨµÀÖд«ÊäÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-033Ñî½ÜÒ»ÖÖº¬ßÁົ·õ£ë껯ºÏÎïµÄºÏ³É¡¢±íÕ÷¼°ÆäÓëCT-DNAµÄÏ໥×÷ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-034ÍòȺӦÓÃÖÐ×ÓÑÜÉä¼¼ÊõÑо¿ÌÇÜÕøµÄÖÊ×Ó»¯×´Ì¬ºÍÇâ¼üÍøÂçÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-035ÍõÓîçùCathepsin BÏìÓ¦µÄÈÜøÌå°ÐÏòÓ«¹â̽Õë¼°ÆäÔÚϸ°û³ÉÏñÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-036ºÎÊ¢±óÄÍÒ©ÐÔÖÊÁ£½ÓºÏ´«µÝЧÂʵĸßÁéÃô¡¢¿ìËÙ¶¨Á¿¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-037ÀîÖ¾ÔË»ùÓÚº¬ÌǾۺÏÎï±ÈÂÊÓ«¹âpH̽ÕëµÄºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-038ÆîºÀÂü²»Í¬Ö²ÎïÒÒõ£ôÇËáºÏ³ÉøÑÇ»ù¼äÏ໥×÷ÓõÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-039ÕÅÓªÓªÒÒõ£ôÇËáºÏ³Éø½á¹¹Ñо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-040Òü¾üÝÁ¶þ¼×õ£Ñǰ·Îª¹Ç¼ÜµÄÓ«¹â̽ÕëÔÚ»îϸ°ûÈÜøÌåÖÐÑ¡ÔñÐÔºÍÌØÒìÐÔ¼ì²â¹Èë׸ÊëÄÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-041ÍõÑå¶÷Synthesis of fluorescent bisboronic acid compounds and their recognition to Lewis oligosaccharidesÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-042ÍõÅô³åÀûÓÃAPEXʵÏÖ»îϸ°ûÖпռäÌØÒìÐԵĵ°°××éѧ±ê¼ÇÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-043Áõ¼Ñ´ºSynthesis and the Interaction of 2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-f][1,10]phenanthrolines with Telomere DNA as antitumor agentsÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-044ÖÜÓ±»ùÓÚAPEX¼¼ÊõµÄºËËữѧ±ê¼Çз½·¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-045Âí¸Õµí·ÛÑùµ°°×ÏËά΢¹Û½á¹¹µÄºìÍâ¹âÆ×·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-046ÕԻݸßЧ˫¹â×Ó¼¤·¢¿É½µ½âµÄ½»Ìæ¹²¾ÛÎï×Ô×é×°ÄÉÃ×¾Û¼¯ÌåÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-047ÁõÕܸ´ºÏ¾Ûõ¥ÄÉÃ×̽ÕëÔÚ°ÐÏòÒ¶ËáÊÜÌåµÄ»îÌå¹âÉù³ÉÏñÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-048ÀîТÃôË«ºË½ð£¨¢ñ£©ì¢ÀàºÍ¶þÁò´ú°±»ù¼×ËáÑÎÅäºÏÎïµÄÓ«¹âºÍÌåÍ⿹°©»îÐÔÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-049´ÞÖ¾ÉÁµªÔÓß¹à¤ÑÜÉúÎï×÷ΪEGFRºÍSrcÒÖÖÆ¼ÁµÄÉè¼ÆºÏ³ÉÓ뿹°©»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-050ÐìÔÆÁú3ÖÖ³¤ÑæÃºÓë΢ÉúÎïµÄÈÜúƥÅäʵÑéÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-051Âíç÷»ùÓÚDNAÔÓºÏË®Äý½ººÍȾÁϵÄSNP¿ÉÊÓ»¯Ó«¹â¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-052Ñî¼ÎÀöÄ©¶ËάÉúËØEÐÞÊÎsiRNA¶Ô»ùÒò±í´ïµÄ¹âµ÷¿ØÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-053ÍõÊéÏã·¦ÑõºÍ¹âÕÕË«¿ØµÄÐÂÐÍÕï¶ÏÖÎÁÆÇ°-ǰҩµÄ¹¹½¨ÓëÌåÍâϸ°û¶¾ÐÔÆÀ¼ÛÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-054ÁÖãüÓò°ÐÏò»¯Ñ§Æ½Ì¨T-REXµÄ¹¹½¨¼°ÆäÔÚÑõ»¯»¹Ô­ÐźÅͨ·Ñо¿·½ÃæµÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-055ÐìÖ¾±óPleuromutilin derivatives: From antibiotics to antidiabeticsÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-056°²îÚÀ¤ÀûÓÃClick½»Áª·´Ó¦ÒýÈëÅäÌåGAlNAcÒÔ¶ÔsiRNA½øÐй¦ÄÜ»¯ÐÞÊÎÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-057¹ùäì¼ÑÉßÂéͪ¼°Í¬ÏµÎïÒìÔ´ÉúÎïºÏ³É;¾¶¹¹½¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-058ºî¾²ÀöС³¦°ÐÏòÊÍ·ÅNO¹©Ìå¼°Æä´ÙÒ©ÎüÊÕµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-059֣˹ÆëÀûÓõ°°×Öʼ¤»î²ßÂÔÑо¿MAPKͨ·µÄÐźŴ«µÝ¹ý³ÌÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-060»ÆÓ»ùÓÚÉúÎïºÏ³ÉºÍºÏ³É»¯Ñ§µÄÌìÈ»²úÎïÒ©Îï·¢ÏÖºÍÑÜÉúÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-061κ·æÆ«Õñ·Ö±æºÍƵÕñ¶¯¹âÆ×ϵͳ£ºÒ»¸ö¶àÓÃ;µÄ½çÃæºËËá½á¹¹Ó붯Á¦Ñ§¼ì²âƽ̨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-062ÍõÊØ·æÁòÁ´Ë¿¾úËØÉ±Ãð°ûÄÚ¼ÄÉú¾úµÄ×÷ÓûúÖÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-063²ÌÓîßÁ¿©²¢ßÁ¿©¶þͪÔÚÖ×Áö¹âÕïÁÆÉϵÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-064³ÂÑ©Èð˳²¬+À×ÅÁÃ¹ËØ/3-¼×»ùÏÙàÑßÊ»ìºÏÒ©Îï¶ÔHeLaϸ°û×ÔÊɵÄÓ°ÏìÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-065ÕÅ´äMn-TAT-PTD-NgbµÄÉñ¾­±£»¤×÷ÓÃÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-066Áõµ¤µ¤¶àÖÖÊôµÄÔ­ß²ßøÔ­Ñõ»¯Ã¸µÄ¶¯Á¦Ñ§ÐÔÖÊÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-067ÀîÔÃÇà±ú¹û»¨½·õ£°·¼°ÀàËÆÎïµÄºÏ³ÉÓ뿹ѪС°å¾Û¼¯»îÐÔÆÀ¼ÛÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-068³Â³É°ÐÏòÐÔsiRNAÄÉÃ׸øÒ©ÌåϵµÄ¹¹½¨ºÍ±íÕ÷Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-069ÓÚÃ÷À¤4-¼×Ñõ»ù±½¼×È©-4-ôÇ»ù±½ÒÒõ£ëêµÄºÏ³É¼°Óëct-DNAµÄÏ໥×÷ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-070лФ²¶×½µ°°×-µ°°×Ï໥×÷ÓõÄË«¹¦ÄÜ̽ÕëÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-071³µÍ¨¶ËÁ£G-ËÄÁ´ÌåÅäÌ壺ÌìÈ»²úÎïSchizocommuninÑÜÉúÎïµÄÉè¼Æ¡¢ºÏ³ÉÓëÆÀ¼ÛÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-072½ªÎõ»ùÓÚÀ¥³æ¼¸¶¡ÖÊø½á¹¹µÄÒÖÖÆ¼ÁɸѡÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-073Õű̲¨Ò»ÖÖÓÕµ¼µ°°×·ºËØ»¯½µ½âµÄ°Ðµ°°×Ë®½âëIJßÂÔÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-074ÑîìÚ¾ßÓÐÖÊÆ×±êÇ©×ªÒÆ¹¦ÄܵĹ⽻ÁªÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-075Íõ˼¼ÑFormation and Stabilization of The Human Telomeric Repeats-Containing RNA G-quadruplex by Benzothioxanthene Derivatives with Anti-tumor ActivityÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-076ÀîÊ«Á¼À´Ô´ÓÚÌìÈ»²úÎïµÄÐÂÐͳ¤Ð§DPP-4ÒÖÖÆ¼ÁµÄ·¢ÏÖºÍÉè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-077Íõ²ÊϼÏßÁ£ÌåÄÚ¹Èë׸ÊëıÈÀýÓ«¹â³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-078Î̽ðÅôDNAzyme½»ÁªË®Äý½ºµÄÖÆ±¸¼°ÆäÔÚÆÏÌÑÌǼì²âÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-079ÑîË®À¼Î¢ÉúÎïÈܽâÄÚÃɹźÖúӰÏìÒòËØ¼°²úÎï·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-080³ÂçùÐÂÐ͵ÄË«µ×ÎïÀàËÆÎïµÄ¼¸¶¡ÖʺÏøÒÖÖÆ¼ÁÉè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-081ÓÚÓ¾·ÉO-Á×õ£»¯Ë¿°±ËáÑÜÉúÎïÖÆ±¸¼°»úÀíÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-082³É÷Screening of Antitumor Activity of the Novel Phenanthroline DerivativesÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-083Åí·É»ùÓÚ¹èÄÉÃ×ÏßµÄÒ©ÎïÔØÌå½øÐа©Ö¢ÖÎÁÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-084ÖÜÑ×·é»ùÓÚÐãÀöÒþ¸ËÏß³æµÄÓ«¹â¹èÄÉÃ׿ÅÁ£µÄ¶¾ÐÔÆÀ¼Û¼°°ÐÏò·Ö×Ó³ÉÏñÓ¦ÓÃÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-085³Âѧ»Ýº¬ÈýßòµÄºËËá°ÐÏò¿¹°©Ò©ÎïµÄºÏ³É¼°»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-086Uzair AlamSynthesis of Zidovudine derived [12]aneN3 Compounds and Their Interaction with DNAÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-087³Â»áÓ¢¿Ç¾ÛÌǽÓÖ¦PEI·Ç²¡¶¾»ùÒòÔØÌåµÄ¾ùÏàºÏ³É¼°Æä»ùÒòתȾÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-088ÕÅÑǸÕÖÐÒ©Ó뻯ѧ-ÖвÝÒ©µÄδÀ´ÓëÌôÕ½Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-089Àî½ð²¨Î¢Ð¡ºËÌǺËËáµÄ»¯Ñ§·Ö×Ó̽ÕëÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-090Ç®ÒæÆ½Ñõ»¯¶þßòÓ«¹â̽ÕëÔÚѪÎü³æ³É³æÖгÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-091Íõ½Üîٽ鵼µÄÉúÎïÕý½»¶Ï¼ü·´Ó¦µÄ¿ª·¢¼°Ó¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-092Íõ×ÓºÌBcl-2¼Ò×åµ°°×½áºÏÒÖÖÆ¼ÁµÄºÏ³ÉºÍÓÅ»¯Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-093Íõµ¤ÀûFe@Fe3O4ÄÉÃ×Á£×ÓÔÚMRI/´ÅÈÈÖÎÁÆÖеÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-094ÑîÊËÆ½¶à¹¦ÄÜ´ÅÐÔÄÉÃײÄÁÏÔÚÖ×ÁöÕïÁÆÒ»Ì廯ÖеÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-095Àî¿Ë½¨ÒÒõ£¸¨Ã¸AôÈ»¯Ã¸³ý²Ý¼ÁµÄ¿¹ÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-096¶¡ÉÛÕäEcoSynther¡ªE.coliÉúÎïºÏ³ÉDZÁ¦ÍÚ¾òÄÜÊÖÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-097ÂÀ½£À¥Õë¶ÔFLT3¼°ÆäÍ»±äµÄµûà¤ÍªÀàÒÖÖÆ¼ÁµÄÓÅ»¯Éè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-098 Ðì¿Ë»¨ÑÇÎøËáÄÆÓÕµ¼Ö×Áöϸ°ûµòÍö¹ý³ÌÖÐÎø´¼ºÍ¹ýÑõ»¯ÇâµÄͬʱ¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-099³Âº£ÑóµÚÈý´úEGFR-T790MÒÖÖÆ¼ÁµÄ·¢ÏÖÓëÓÅ»¯Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-100ÁõÑ×¾þ¶àÖÖ¾ßÓÐÉñ¾­ÓªÑø»îÐÔµÄÁ×Ö¬õ£ÌÇÜյĸ·¨ºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-101ÁõΰҰÉúÓ£ÌÒÀîÒ¶ÒÖÖÆ¦Á-ÆÏÌÑÌÇÜÕø»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-102ºÎµ¤conditionally disordered chaperones confer programmed specificity to defend stressÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-103²ÌÀû·æÀûÓöàëÄÆ¬¶ÎÏ໥×÷ÓòßÂÔÑо¿¶¯Ì¬½á¹¹±ä»¯µ°°×ÖʵķÖ×Ó×÷ÓÃȫòÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-104»Æ¸ÕÁ¼¶àÌǵÄÑÜÉú»¯·½·¨¼°ÉúÎï»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-105·®æÃæÃ»ùÓÚÑõ»¯Ê¯Ä«Ï©¿ÉÊÍ·ÅÐÍÊÊÅäÌåDNAÉúÎï´«¸ÐÆ÷ÐźŷŴó¼ì²âATPÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-106ÍõÓñÇàNM23-H2/G4×è¶Ï¼Á£ºIsaindigotoneÀ໯ºÏÎïµÄÉè¼Æ¡¢ºÏ³É¼°ÆÀ¼ÛÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-107ÍõÀÚɸѡ·ÇÌìÈ»¸¨Òò×Ó¸ßЧתÔ˵°°×Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-108ÁõÏòÈÙÈÈ´ø¼ÙË¿½Íĸ¾úÈܽâÉñ¸®ÃºµÄʵÑéÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-109֣ͩС·Ö×ÓÆÆ»µE3½ÓÍ·µ°°×SPOP-µ×ÎïÏ໥×÷ÓÃÓëÉö°©ÖÎÁÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-110ÁÎÑÞ¾êÄÉÃ×Cu2O¹â´ß»¯É±¾úµÄԭλÈȶ¯Á¦Ñ§Ñо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-111Öì´óDZNADPHÑõ»¯Ã¸(NOX)ÒÖÖÆ¼Á»·¶þ·¼»ùµâæfÑεĿ¹Ö×ÁöÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-112ÍôÏþÆ½ÖØÒªÄ£ÄâÌìȻҽҩÖмäÌå4-±½»ù-2-¼×»ù-5-Ñõ-Âðßø-3-ôÈËáµÄÖÆ±¸¼°Æä»¹Ô­·´Ó¦ÐÔÌí¼Óµ½ÎÒµÄÈÕ³Ì
»á³¡£º×ۺϽÌѧ1ºÅÂ¥
10:05-12:0528-A-001Íô¸£ÒâÖÐÒ©»îÐԳɷÖÓ«¹â̽ÕëµÄ¹¹½¨ºÍ³ÉÏñÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-002Âí¼Ñ»ÛÌìÈ»»ÆÍªÀàMAGLÒÖÖÆ¼ÁµÄ·¢ÏÖÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-003¸¶Ó¢½ÜÒ©ÎïÓëÄÉÃ×½ð²»Í¬Á¬½Ó·½Ê½µÄ±È½Ï¼°Æä¿¹°©»îÐÔµÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-004Ò¶×Ó²»¿ÉÄæµ°°×¼¤Ã¸ÒÖÖÆ¼Á°Ð±êµ°°×µÄ»¯Ñ§µ°°×ÖÊ×éѧ·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-005ÐÏÑÞÁὪ»ÆËØ-à×à¤ÍªÔÓºÏÌåµÄºÏ³É¼°ÉúÎï»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-007ÀîÑÇʤͭÂ̼ٵ¥°û¾úÐÂÐÍȺÌå¸ÐÓ¦ÐźÅIQSÀàËÆÎïµÄÉè¼Æ¡¢ºÏ³ÉÓë»îÐÔ³õ̽Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-008³ÂÓ°Ç×µçÖ¬ÖÊ·Ö×ÓÐÞÊÎλµãµÄ¶¨Á¿»¯Ñ§µ°°×ÖÊ×éѧÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-010ÆëлÃôת»ùÒòÃ޺ͳ£¹æÃÞÖÖÖ²µØÍÁÈÀÕæ¾úȺÂä¶àÑùÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-011YuchaoYaoSynthesis of water soluble triphenylethylene-coumarin hybrids bearing 2-oligoethoxy ethanamine side chain end-labeled with tertiary amino groupsÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-012ÈÄˬDNA¼×»ù»¯¶àλµã¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-014Òü¾üÒ»ÖÖ»ùÓÚµ¤»Çõ£ÂȵÄÁò»¯ÇâÓ«¹â̽Õ뼰ϸ°û³ÉÏñÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-015ËλÀȨßÁßòÒøÅäºÏÎïµÄ¿¹Ö×ÁöÐÔÖÊÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-016ÍõÁ¦[Mo36O108(NO)4(H2O)16].52H2OµÄºÏ³É¼°Æä¶ÔÀÒ°±ËáøµÄÒÖÖÆ×÷ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-017ÂÞȺ¾ßÓÐʱ¼ä·Ö±æÓ«¹âÌØÐÔµÄÉúÎï»îÐÔÓ«¹â̽Õë¼°ÆäÔÚϸ°û³ÉÏñÖеÄÓ¦ÓÃÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-018³ÂÓñÄÈMDM2 and scorpion active peptide BmK AGP-SYPU2 mode of action predictionÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-019ÀîÐÄê¿Ò½Óø߷Ö×Ó/HAÈýÔª¹ÇÖ²ÈëÌ帴ºÏ²ÄÁϵÄÖÆ±¸ÓëÐÔÄÜÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-021ËÎÏþÁÕ¼¸ÖÖÊÐÊÛ½ÍËØµÄ¿¹Ñõ»¯ÄÜÁ¦µÄ±È½ÏÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-022ÇØÎª¶¨Á¿µ°°×ÖÊ×éѧ½ÒʾO-GlcNAcÐÞÊÎÎȶ¨Æäµ×Îïµ°°×Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-023ÕÅÝíÏßÁ£ÌåºôÎüÁ´¸´ºÏÎïµÄ½á¹¹Óë×÷ÓûúÀíÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-024ÂíѩƼ¸ßÁéÃô¸ßÌØÒì¿ÉÊÓ»¯¼ì²âHIV²¡¶¾µÄÄÉÃ×¼ì²â¼¼ÊõÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-025ÁõæÃæÃ»Ç´ïÀàËÆÎïRrt1.17µÄ±íÕ÷¼°ÆäÌåÄÚ¿¹ÑªË¨»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-026Íõ¿µÁ½ÖÖÈËÔ´ÒÒõ£µ¨¼îÊÜÌåÑÇÐÍÆÀ¼ÛÄ£Ð͵Ĺ¹½¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-027κЦµªÔÓÌÇÐÞÊεÄÝÁ¶þõ£Ñǰ·ÀàÑÜÉúÎïµÄÉè¼Æ¼°ºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-028´÷½¨Òµ»ùÓÚ»¯Ñ§µ°°×ÖÊ×éѧµÄ»ÆÜËÜÕ¿¹¸ÎÔàÖ¬·¾»¯»úÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-029ºúÏþÃ÷ÐÎ̬¿Éµ÷¿ØµÄÓ«¹âÄÉÃ×Á£×ӵĺϳɣ¬¹âÎïÀíÐÔÖʼ°ÆäË«¹â×Óϸ°û³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-030ÅíÊ¥Ã÷Design, synthesis, advanced glycation end-products and ¦Á-glucosidase inhibition in vitro of diosmetin derivatives Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-031·¶±üÁÕÁ×îâÀ¶×÷Ϊ¹âÆ×̽ÕëÊÔ¼Á²â¶¨ÁòÆÕÂÞÄþÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-032Íõ½ðÌΰ±¼×õ£»ù¸Ê¶ÌÇÐÞÊÎÝÁõ£Ñǰ·ÑÜÉúÎïµÄºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-033ËθßÅôËÄÇâÒìà­ßøÑÜÉúÎï×÷ΪPDE4ÒÖÖÆ¼ÁµÄÉè¼Æ¡¢ºÏ³É¼°ÉúÎï»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-034ÀîºìÑà°åÀõ¶àÌÇ-ÎøÄÉÃ×Á£×Ó¸´ºÏÎïµÄÖÆ±¸¡¢±íÕ÷¼°¿¹Ö×Áö»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-035³Â±ò°±¼×»ùßßà¤ÑÜÉúÎïÐÞÊÎË«ÝÁõ£Ñǰ·»¯ºÏÎïµÄºÏ³ÉÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-036ÇØÃúÔó»ùÓÚ°±»ùà×ऽṹµÄEGFR T790MÒÖÖÆ¼ÁÉè¼Æ¼°»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-037½ªÖ¾»Ô»¯ºÏÎïµÄ¿¹Î¢ÉúÎï»îÐÔÃâ·Ñɸѡƽ̨:CO-ADDÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-038ÀîÏòÈÙL-¿¹»µÑªËᣬ¦Á-ÉúÓý·Ó£¬Ô­»¨ÇàËØB3£¬¦Â-ºúÂܲ·ËغÍϺÇàËØÓëÈܾúøÏ໥×÷ÓûúÖÆÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-039ÌÆ¾ýÔ´1,3,4-àç¶þßòϯ·ò¼îÀÒ°±ËáøÒÖÖÆ»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-040Òü¾üIR-780Ñ¡ÔñÐԵļì²â2 - °±»ù±½Áò·ÓÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-041ÈÖÈðÑ©ÊÖÐÔ°±»ù´¼ÐÞÊÎÝÁõ£Ñǰ·ÑÜÉúÎïµÄ¿¹Ö×ÁöÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-042Li WuNucleotide incorporation across from templating L-nucleoside by DNA polymerasesÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-043ãÆÏþ¸ÙÌìÈ»ASIC3/ASIC1aÑ¡ÔñÐÔÒÖÖÆ¼ÁµÄ·¢ÏÖÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-044ÕÔÖÞÒ»ÖÖÐÂÐÍturn-onÓ«¹â̽ÕëÓÃÓÚ¼ì²âÈý±½»ùì¢Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-045¶­´¨ÐÂÐͱ½²¢àçßòÑÜÉúÎï×÷ΪpHÓ«¹â̽ÕëÓ¦ÓÃÓÚϸ°û³ÉÏñÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-046Ò¦¸êÓóÂݶ¾ÏÙ¹Üת¼×é²âÐò×é×°¼°¶¾Ëغϳɹ¦Äܵ°°×·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-047ÁõƽÏÈCYP119øͻ±äÌå¶Ô˳ʽ-b-¼×»ù±½ÒÒÏ©ÀàËÆÎï²»¶Ô³Æ»·Ñõ»¯·´Ó¦µÄÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-048³ÂÍþ»ùÓÚNAG ¨CthiazolineµÄ84¼Ò×åÌÇ»ùË®½âÃ¸ÌØÒìÐÔÒÖÖÆ¼ÁµÄÉè¼ÆÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-049Íõð¥Àö±´úÍéÌþÍѱøµÄÑ¿°û±íÃæÕ¹Ê¾¼¼ÊõÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-050¿µ¶«Î°First Discovery of Novel 3-Hydroxy-quinazoline-2,4(1H,3H)-diones as Anti-Vaccinia and Adenovirus Agents via ¡°Privileged Scaffold¡± Refining ApproachÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-051³Ìö¦Óлú·Ö×Ó¶ÔRNAµÄ½µ½âºÍ¹¦ÄÜÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-052Ñîçù»ùÒòÃÜÂë×ÓÀ©Õ¹¼¼Êõͨ¶Áµ¥»ùÒòÒÅ´«²¡µÄ½Ø¶Ìµ°°×Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-053Àîäì»ùÓڰеã½á¹¹µÄÐÂÐÍDAPYÀàHIV-1 NNRTIsµÄÉè¼Æ¡¢ºÏ³É¼°»îÐÔÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-054¸ßƼÐÂÐÍßÁà¤æéà×à¤ÍªÀàÑÜÉúÎïµÄÉè¼Æ¡¢ºÏ³ÉÓëÉúÎï»îÐÔÆÀ¼ÛÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-055³ÂÀÚ»ùÓÚÀ¥³æÌÇ»ùË®½âøµÄÒÖÖÆ¼ÁɸѡÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-056ÆëΰÄлùÓÚ½ðÄÉÃ״صÄÉúÎï°·Ó«¹â¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-057½­ººÅôÑõ»¯ï¯¹è½º¸´ºÏÕûÌåÖùÔÚÏß¹ÌÏàÝÍÈ¡-ÖÊÆ×·ÖÎöÓÃÓÚÐÞÊκËÜյķÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-058»Æ²®ÊÀ»ùÓÚÓÅÊÆ½á¹¹Æ¬¶ÎºÏÀí×éºÏµÄ·Ö×ÓÔӺϲßÂÔ·¢ÏÖHIV-1ÒÖÖÆ¼ÁÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-059°²Ïþ¸Õ»ùÓÚ½ðÄÉÃ״صľ«°·µçÖ»¯Ñ§·¢¹â£¨ECL£©¼ì²âÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-060ФçñÒ»ÖÖ»ùÓڹ⼤»îÊÊÅä×ÓÓ«¹â¼ì²â°©Ö¢²¿Î»µÄ·½·¨Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-A-061Ðܾü»¯Ñ§ÑÜÉú-ÖÊÆ×·ÖÎöÓÃÓÚDNAºÍRNAÖÐôǼ׻ùºÍÈ©»ù°ûà×à¤ÐÞÊεĸßÁéÃô·ÖÎöÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-113¸»²©Ê¶6-¼×»ùÏÙàÑßʵÄÁ¦³¡¹¹½¨¼°·Ö×ÓÄ£ÄâÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-114³ÂÓñç÷»ùÓÚ´¸Í·×´ºËø½á¹¹µÄmiRNA-221º£Ãà±í´ïÔØÌåµÄ¹¹½¨¼°ÆäÐÔÄÜÑо¿Ìí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-114ËÎÑàÑàpH¶ÔС·Ö×Óµ÷¿ØÄýѪø»îÐÔʵÑéµÄÓ°ÏìÌí¼Óµ½ÎÒµÄÈÕ³Ì
10:05-12:0528-P-115Åí˫ӦÓÃÓлú¿ò¼Ü²ÄÁϼì²âmicroRNAÌí¼Óµ½ÎÒµÄÈÕ³Ì

¡¡¡¡±¨¸æ¡¶¡·£¬Ä¿Ç°ÄúµÄÈճ̱íÖй²Óиö±¨¸æ¡£

¡¡

½ØÖ¹ÈÕÆÚ

»áÒé×¢²á£º2016Äê5ÔÂ15ÈÕ

ÂÛÎÄÕ÷¼¯£º2016Äê4ÔÂ15ÈÕ

»áǰ½É·Ñ£º2016Äê5ÔÂ15ÈÕ

Íü¼ÇÃÜÂë

Öйú»¯Ñ§»áÃØÊé´¦

µØ¡¡¡¡Ö·£º±±¾©ÊÐÖйش山һ½Ö2ºÅ
ÁªÏµµç»°£º+86-10-82449177
ÓÊÕþ±àÂ룺100190


´«¡¡¡¡Õ棺+86-10-62568157
Íø¡¡¡¡Ö·£ºhttp://www.chemsoc.org.cn


¸öÈË»áÔ±£ºqiaoqinzhao@iccas.ac.cn
ѧÊõ½»Á÷£ºcmdeng@iccas.ac.cn
¹ú¼ÊÊÂÎñ£ºhanlidong@iccas.ac.cn
»¯Ñ§¾ºÈü£ºwlbai@iccas.ac.cn


ѧÊõ½±Àø£ºyuehe@iccas.ac.cn
ÆÚ¡¡¡¡¿¯£ºhaolinxiao@iccas.ac.cn
µ¥Î»»áÔ±£ºwangyr@iccas.ac.cn
²úѧÑкÏ×÷Óë´Ù½ø£ºbinjiao@iccas.ac.cn


All Rights Reserved by the Chinese Chemical Society¡¡Öйú»¯Ñ§»á °æÈ¨ËùÓÐ ¾©ICP±¸05002797ºÅ

ÃÅ»§ÍøÕ¾¡¢»áԱϵͳ¡¢»áÒéϵͳ ¼¼ÊõÖ§³Ö£ºÉîÛÚÊÐѧÊõ¿Æ¼¼ÓÐÏÞ¹«Ë¾ www.szac.cn

Baidu
map